[go: up one dir, main page]

PE20191346A1 - Un derivado de oxazina base libre en forma cristalina - Google Patents

Un derivado de oxazina base libre en forma cristalina

Info

Publication number
PE20191346A1
PE20191346A1 PE2019001432A PE2019001432A PE20191346A1 PE 20191346 A1 PE20191346 A1 PE 20191346A1 PE 2019001432 A PE2019001432 A PE 2019001432A PE 2019001432 A PE2019001432 A PE 2019001432A PE 20191346 A1 PE20191346 A1 PE 20191346A1
Authority
PE
Peru
Prior art keywords
crystalline form
trifluorometil
theta
refers
compound
Prior art date
Application number
PE2019001432A
Other languages
English (en)
Inventor
Rita Ramos
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20191346A1 publication Critical patent/PE20191346A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A LA FORMA CRISTALINA A DEL COMPUESTO N-(6-((3R,6R)-5-AMINO-3,6-DIMETIL-6-(TRIFLUOROMETIL)-3,6-DIHIDRO-2H-1,4-OXAZIN-3-IL)-5-FLUOROPIRIDIN-2-IL)-3-CLORO-5-(TRIFLUOROMETIL)PICOLINAMIDA CUYO PATRON DE DIFRACCION DE RAYOS X EN POLVO EXPRESADOS EN ANGULO DE REFRACCION 2 THETA PRESENTA LOS SIGUIENTES PICOS: 10.7, 14.8, 18.7, 19.5, 21.4, 21.7, 25.5, 29.9, 35.0 Y 37.8° CUANDO SE MIDE USANDO RADIACION CuK?, DONDE DICHOS VALORES SON MAS O MENOS 0.2° 2 THETA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE BACE SIENDO UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER O ANGIOPATIA AMILOIDE CEREBRAL
PE2019001432A 2017-01-20 2018-01-18 Un derivado de oxazina base libre en forma cristalina PE20191346A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17152481 2017-01-20

Publications (1)

Publication Number Publication Date
PE20191346A1 true PE20191346A1 (es) 2019-09-30

Family

ID=57890668

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019001437A PE20191250A1 (es) 2017-01-20 2018-01-18 Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer
PE2019001432A PE20191346A1 (es) 2017-01-20 2018-01-18 Un derivado de oxazina base libre en forma cristalina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2019001437A PE20191250A1 (es) 2017-01-20 2018-01-18 Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer

Country Status (21)

Country Link
US (2) US20190388428A1 (es)
EP (2) EP3571195A1 (es)
JP (2) JP2020505363A (es)
KR (1) KR20190126291A (es)
CN (1) CN110167535A (es)
AR (1) AR110758A1 (es)
AU (3) AU2018208870A1 (es)
BR (2) BR112019014234A2 (es)
CA (2) CA3046304A1 (es)
CL (1) CL2019002020A1 (es)
CO (2) CO2019007671A2 (es)
CR (1) CR20190333A (es)
IL (2) IL267640A (es)
JO (2) JOP20190180A1 (es)
MX (2) MX2019008603A (es)
PE (2) PE20191250A1 (es)
RU (1) RU2019126022A (es)
SG (2) SG11201905528XA (es)
TW (1) TW201828943A (es)
UY (1) UY37572A (es)
WO (2) WO2018134761A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019142111A1 (en) * 2018-01-18 2019-07-25 Novartis Ag Salt forms of an oxazine derivative bace inhibitor
CN112661667B (zh) * 2020-12-28 2023-02-03 浦拉司科技（上海）有限责任公司 一种三氟乙脒的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2663561T3 (en) 2011-01-13 2016-06-06 Novartis Ag New heterocyclic derivatives and their use in treating neurological disorders

Also Published As

Publication number Publication date
JP2020505367A (ja) 2020-02-20
IL267640A (en) 2019-08-29
EP3570820A1 (en) 2019-11-27
CR20190333A (es) 2019-09-13
US20200048237A1 (en) 2020-02-13
AU2018208870A1 (en) 2019-07-04
CA3048346A1 (en) 2018-07-26
BR112019014825A2 (pt) 2020-02-27
MX2019008601A (es) 2019-09-10
JOP20190178A1 (ar) 2019-07-16
CA3046304A1 (en) 2018-07-26
RU2019126022A (ru) 2021-02-20
WO2018134761A1 (en) 2018-07-26
EP3571195A1 (en) 2019-11-27
US20190388428A1 (en) 2019-12-26
KR20190126291A (ko) 2019-11-11
AR110758A1 (es) 2019-05-02
SG11201905528XA (en) 2019-08-27
AU2020289738A1 (en) 2021-01-21
PE20191250A1 (es) 2019-09-18
CL2019002020A1 (es) 2019-10-04
BR112019014234A2 (pt) 2020-03-17
CN110167535A (zh) 2019-08-23
CO2019007671A2 (es) 2019-07-31
MX2019008603A (es) 2019-09-10
IL268131A (en) 2019-09-26
CO2019007670A2 (es) 2019-07-31
WO2018134760A1 (en) 2018-07-26
RU2019126022A3 (es) 2021-10-19
AU2018209442A1 (en) 2019-06-20
JP2020505363A (ja) 2020-02-20
SG11201905116PA (en) 2019-08-27
JOP20190180A1 (ar) 2019-07-20
TW201828943A (zh) 2018-08-16
UY37572A (es) 2018-08-31

Similar Documents

Publication Publication Date Title
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
CL2019001978A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CY1122046T1 (el) Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
AR101403A1 (es) (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carboxamida, su purificación para su uso como principio activo farmacéutico, un procedimiento para su preparación y su empleo en el tratamiento de enfermedades cardiovasculares
MX2018003215A (es) Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
MX2015015692A (es) Novedosas heteroarildihidropirimidinas, unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de hepatitis b.
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
TR201905009T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
TR201821158T4 (tr) Triazin bileşiği ve bunun tıbbi amaçlarla kullanımı.
MX375372B (es) COMPOSICIONES DE COMPUESTOS DE MOLÉCULA PEQUEÑA Y USO DE LOS MISMOS COMO INHIBIDORES TrKA.
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
PE20191142A1 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CL2015002701A1 (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo
CY1120700T1 (el) Ενωσεις τριαμινοπυριμιδινης χρησιμες για προληψη ή αγωγη ελονοσιας
TR201900680T4 (tr) CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri.
CL2014003607A1 (es) Compuestos derivados de benzodioxol, inhibidores de la acetilcolinesterasa; metodo de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o el tratamiento de la enfermedad de alzheimer.
CL2020000553A1 (es) Compuestos heteroaromáticos sustituidos con cicloolefinas y su uso.
PE20191486A1 (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER